Russia’s first tetravalent vaccine for influenza prevention that meets all WHO recommendations for the number of strains and amount of active substance

Manufacturer – FORT biopharmaceutical company (Nacimbio holding)

Since 2021, the vaccine has been approved for use in children from 6 months, adults without age limit and pregnant women.

Ultriks Kvadri tetravalent influenza vaccine induces specific immunity to two influenza strains A and two influenza strains B and contains 15 µg of antigens of each of the strains with a total amount of 60 µg. The preparation does not contain any preservatives, stabilizers and adjuvants - substances used to create a stronger immune response.

Ultriks Kvadri is a formulation developed by Russian researchers and is produced by Nacimbio holding using the full production cycle - from antigen development to a finished dosage form.

The vaccine composition meets the current recommendations of the World Health Organization for influenza preventive preparations.